

ALTRES PUBLICACIONS
OTRAS PUBLICACIONES
OTHER PUBLICATIONS

- Cabello J, Sämann J, Gómez-Orte E, Erazo T, Coppa A, Pujol A, Büssing I, Schulze B, **Lizcano JM**, Ferrer I, Baumeister R, Dalfó E.
pdr-1/hParkin negatively regulates the phagocytosis of apoptotic cell corpses in C.elegans.
Cell Death and Disease. 5 (2014)
- Erazo T, Moreno A, Ruiz-Babot G, Rodríguez-Asiain A, Morrice NA, Espadamala J, Bayascas JR, Gómez N, **Lizcano JM**.
Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex.
Mol Cell Biol. 33: 1671-86. (2013)
- Elkins JM, Wang J, Deng X, Pattison MJ, Arthur JS, Erazo T, Gomez N, **Lizcano JM**, Gray NS, Knapp S..
X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor.
J Med Chem. 56: 4413-21 (2013)
- Deng X, Elkins JM, Zhang J, Yang Q, Erazo T, Gomez N, Choi HG, Wang J, Dzamko N, Lee JD, Sim T, Kim N, Alessi DR, **Lizcano JM**, Knapp S, Gray NS.
Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Eur J Med Chem. 70C: 758-767 (2013)
- Zurashvili T, Cordón-Barris L, Ruiz-Babot G, Zhou X, **Lizcano JM**, Gómez N, Giménez-Llort L, Bayascas JR.
Interaction of PDK1 with phosphoinositides is essential for neuronal differentiation but dispensable for neuronal survival.
Mol Cell Biol. 33: 1027-40. (2013)
- Gil E, Bosch A, Lampe D, **Lizcano JM**, Perales JC, Danos O, Chillón M..
Functional characterization of the human mariner transposon hsmar2
PLoS One. 8(9):e73227 (2013)

- Villagrasa P, Díaz VM, Viñas-Castells R, Peiró S, Del Valle-Pérez B, Dave N, Rodríguez-Asiain A, Casal JI, **Lizcano JM**, Duñach M, García de Herreros A.
Akt2 interacts with Snail1 in the E-cadherin promoter.
Oncogene. 31:4022-33 (2012).
- Espona-Fiedler M, Soto-Cerrato V, Hosseini A, **Lizcano JM**, Guallar V, Quesada R, Gao T, Pérez-Tomás R.
Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclox.
Biochemical Pharmacology 83:489-96 (2012)
- Rodríguez-Asiain A, Ruiz-Babot G, Romero W, Cubí R, Erazo T, Biondi RM, Bayascas JR, Aguilera J, Gómez N, Gil C, Claro E, **Lizcano JM**.
Brain Specific Kinase-1 BRSK1/SAD-B associates with lipid rafts: modulation of kinase activity by lipid environment.
Biochim Biophys Acta. Mol Biol Cell Lipids 1811:1124-35 (2011).
- Iñesta-Vaquera FA, Campbell DG, Tournier C, Gómez N, **Lizcano JM**, Cuenda A.
Alternative ERK5 regulation by phosphorylation during the cell cycle.
Cellular Signalling 22:1829-37 (2010)
- Paoletti, P; Vila, I; Rifé, M; **Lizcano, JM**; Alberch, J; Ginés, S
Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5
Journal of Neuroscience 28: 10090-101. (2009)
- Jalaeel M, McBride A, **Lizcano JM**, Deak M, Toth R, Morrice NA, Alessi DR.
Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate.
FEBS Letters 579: 1417-1423. (2005)
- **Lizcano JM**, Goransson O, Toth R, Deak M, Morrice N, Boudeau J, Hawley SA, Udd L, Makela T, Hardie DG, Alessi DR.
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.
EMBO Journal. 23: 833-843. (2004)
- Canto C, Suarez E, **Lizcano JM**, Grio E, Sheperd PR, Fryer LGD, Bertran J, Palacin M, Zorzano A & Guma A
Neuroregulin signaling on glucose transport in muscle cells
Journal of Biological Chemistry 279:12260-12268. (2004)

- Schutkowski M, Reimer U., Panse S, **Lizcano JM**, Alessi D & Scheider-Mergener
High-content peptide microarrays for deciphering kinase specificity and biology.
Angewandte Chemie International Edition 43: 2671-2674. **(2004)**

- **Lizcano JM**, Alrubaie S, Kieloch A, Deak M, Leever SJ & Alessi DR.
Insulin-induced Drosophila S6 kinase activation requires Protein kinase B and Phosphoinositide 3-kinase.
Biochemical Journal. 374: 297-306. **(2003)**

- Dalfo E, Hernandez M, **Lizcano JM**, Tipton KF, Unzeta M.
Activation of human semicarbazide-sensitive amine oxidase by a low molecular weight component present in human plasma.
Biochimica Biophysica Acta (Molecular Basis Disease) 1638: 278-86 **(2003)**

- Perez V, Romera M, **Lizcano JM**, Marco JL, Unzeta M.
Protective effect of N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine (PF9601N), a novel MAO-B inhibitor, on dopamine-lesioned PC12 cultured cells.
Journal of Pharmacy & Pharmacology, 55: 713-716. **(2003)**

- O'Sullivan M, MacDougall MB, Unzeta M, **Lizcano JM**, Tipton KF.
Semicarbazide-sensitive amine oxidases in pig dental pulp.
Biochimica et Biophysica Acta, 1647: 333-336 **(2003)**

- Biondi RM, Komander D, Thomas CC, **Lizcano JM**, Deak M, Alessi DR, van Aalten DM.
High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site.
EMBO Journal, 21: 4219-28 **(2002).**

- **Lizcano JM**, Deak M, Morrice N, Kieloch A, Hastie CJ, Dong L, Schutkowski M, Reimer U & Alessi DR.
Molecular basis for the substrate specificity of NIMA-related kinase-6 (NEK6). Evidence that NEK6 does not phosphorylate the hydrophobic motif of ribosomal S6 protein kinase and serum- and glucocorticoid-induced protein kinase in vivo.
Journal of Biological Chemistry, 277: 27839-49 **(2002).**

- **Lizcano JM**, Alessi DR.
The insulin signalling pathway.
Current Biology, 12: R236-8 **(2002).**

- Ferrer I, **Lizcano JM**, Hernandez M, Unzeta M.

Overexpression of semicarbazide- sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

Neuroscience Letters, 32: 21-24 **(2002)**